Amitava Banerjee
A5072175850- Long-Term Effects of COVID-19
- COVID-19 Clinical Research Studies
- Atrial Fibrillation Management and Outcomes
- COVID-19 and healthcare impacts
- Health Systems, Economic Evaluations, Quality of Life
- Global Public Health Policies and Epidemiology
- Intensive Care Unit Cognitive Disorders
- Health disparities and outcomes
- Healthcare cost, quality, practices
- Blood Pressure and Hypertension Studies
- Cardiac Arrhythmias and Treatments
- Global Health Care Issues
- Chronic Disease Management Strategies
- Diabetes Treatment and Management
- COVID-19 and Mental Health
- Heart Failure Treatment and Management
- Climate Change and Health Impacts
- Antiplatelet Therapy and Cardiovascular Diseases
- Cardiovascular Function and Risk Factors
- Venous Thromboembolism Diagnosis and Management
- Acute Myocardial Infarction Research
- Acute Ischemic Stroke Management
- Cardiovascular Health and Risk Factors
- COVID-19 epidemiological studies
- Primary Care and Health Outcomes
University College London
2016-2025
Barts Health NHS Trust
2020-2025
University College London Hospitals NHS Foundation Trust
2020-2025
Royal London Hospital
2020-2024
Farr Institute
2015-2024
British Heart Foundation
2019-2024
Health Data Research UK
2019-2024
National Health Service
2021-2024
St Bartholomew's Hospital
2019-2024
Amrita Institute of Medical Sciences and Research Centre
2018-2024
<h2>Summary</h2><h3>Background</h3> As mortality rates decline, life expectancy increases, and populations age, non-fatal outcomes of diseases injuries are becoming a larger component the global burden disease. The Global Burden Diseases, Injuries, Risk Factors Study 2016 (GBD 2016) provides comprehensive assessment prevalence, incidence, years lived with disability (YLDs) for 328 causes in 195 countries territories from 1990 to 2016. <h3>Methods</h3> We estimated prevalence incidence 2982...
BackgroundThe Global Burden of Diseases, Injuries, and Risk Factors Study 2015 provides an up-to-date synthesis the evidence for risk factor exposure attributable burden disease. By providing national subnational assessments spanning past 25 years, this study can inform debates on importance addressing risks in context.MethodsWe used comparative assessment framework developed previous iterations Disease to estimate deaths, disability-adjusted life-years (DALYs), trends by age group, sex,...
The burden of cardiovascular diseases (CVDs) remains unclear in many regions the world. GBD (Global Burden Disease) 2015 study integrated data on disease incidence, prevalence, and mortality to produce consistent, up-to-date estimates for burden. CVD was estimated from vital registration verbal autopsy data. prevalence using modeling software health surveys, prospective cohorts, system administrative data, registries. Years lived with disability (YLD) were by multiplying weights. life lost...
<h3>Importance</h3> Elevated systolic blood (SBP) pressure is a leading global health risk. Quantifying the levels of SBP important to guide prevention policies and interventions. <h3>Objective</h3> To estimate association between at least 110 115 mm Hg 140 or higher burden different causes death disability by age sex for 195 countries territories, 1990-2015. <h3>Design</h3> A comparative risk assessment loss related SBP. Estimated distribution was based on 844 studies from 154 (published...
The scale-up of tobacco control, especially after the adoption Framework Convention for Tobacco Control, is a major public health success story. Nonetheless, smoking remains leading risk early death and disability worldwide, therefore continues to require sustained political commitment. Global Burden Diseases, Injuries, Risk Factors Study (GBD) offers robust platform through which global, regional, national progress toward achieving smoking-related targets can be assessed.We synthesised 2818...
A key component of achieving universal health coverage is ensuring that all populations have access to quality care. Examining where gains occurred or progress has faltered across and within countries crucial guiding decisions strategies for future improvement. We used the Global Burden Diseases, Injuries, Risk Factors Study 2016 (GBD 2016) assess personal health-care with Healthcare Access Quality (HAQ) Index 195 territories, as well subnational locations in seven countries, from 1990 2016.
Abstract Objective To quantify rates of organ specific dysfunction in individuals with covid-19 after discharge from hospital compared a matched control group the general population. Design Retrospective cohort study. Setting NHS hospitals England. Participants 47 780 (mean age 65, 55% men) and discharged alive by 31 August 2020, exactly to controls pool about 50 million people England for personal clinical characteristics 10 years electronic health records. Main outcome measures Rates...
Background— Acute aortic dissection is a preventable life-threatening condition. However, there have been no prospective population-based studies of incidence or outcome to inform an understanding risk factors, strategies for prevention, projections future clinical service provision. Methods and Results— We prospectively determined outcomes all acute dissections in population 92 728 Oxfordshire, United Kingdom, from 2002 2012. Among 155 patients with 174 events, 54 had 59 thoracoabdominal...
National levels of personal health-care access and quality can be approximated by measuring mortality rates from causes that should not fatal in the presence effective medical care (ie, amenable mortality). Previous analyses to health only focused on high-income countries faced several methodological challenges. In present analysis, we use highly standardised cause death risk factor estimates generated through Global Burden Diseases, Injuries, Risk Factors Study (GBD) improve expand...
BackgroundIn September, 2015, the UN General Assembly established Sustainable Development Goals (SDGs). The SDGs specify 17 universal goals, 169 targets, and 230 indicators leading up to 2030. We provide an analysis of 33 health-related SDG based on Global Burden Diseases, Injuries, Risk Factors Study 2015 (GBD 2015).MethodsWe applied statistical methods systematically compiled data estimate performance for 188 countries from 1990 2015. rescaled each indicator a scale 0 (worst observed value...
BackgroundThe medical, societal, and economic impact of the coronavirus disease 2019 (COVID-19) pandemic has unknown effects on overall population mortality. Previous models mortality are based death over days among infected people, nearly all whom thus far have underlying conditions. Models not incorporated information high-risk conditions or their longer-term baseline (pre-COVID-19) We estimated excess number deaths 1 year under different COVID-19 incidence scenarios varying levels...
Objective To assess medium-term organ impairment in symptomatic individuals following recovery from acute SARS-CoV-2 infection. Design Baseline findings a prospective, observational cohort study. Setting Community-based two UK centres between 1 April and 14 September 2020. Participants Individuals ≥18 years with persistent symptoms infection age-matched healthy controls. Intervention Assessment of by standardised questionnaires (EQ-5D-5L, Dyspnoea-12) organ-specific metrics biochemical...
In the Global Burden of Disease Study 2013 (GBD 2013), knowledge about health and its determinants has been integrated into a comparable framework to inform policy. Outputs this analysis are relevant current policy questions in England elsewhere, particularly on inequalities. We use GBD data mortality causes death, disease injury incidence prevalence analyse burden as whole, English regions, within each region by deprivation quintile. also assess attributable potentially preventable risk...
The concept of net clinical benefit has been used to quantify the balance between risk ischaemic stroke (IS) and intracranial haemorrhage (ICH) with use oral anticoagulant therapy (OAC) in setting non-valvular atrial fibrillation (AF), shown that patients at highest thromboembolism gain greatest from OAC warfarin. There are no data for new OACs, is, dabigatran, rivaroxaban apixaban, as yet. We calculated balancing IS against ICH using Danish National Patient Registry on AF 1997-2008,...